Los Angeles, California, United States The main office of represented VC is situated in the Los Angeles. The company was established in North America in United States.
Among the most popular fund investment industries, there are Chemical, Health Diagnostics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, Arno Therapeutics, Kronos Bio. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
The top amount of exits for fund were in 2018. Deals in the range of more than 100 millions dollars are the general things for fund. The important activity for fund was in 2018. Comparing to the other companies, this Bellco Capital performs on 38 percentage points more the average number of lead investments. The fund is generally included in less than 2 deals every year.
We also calculated 1 valuable employee in our database.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Bellco Capital, startups are often financed by UTA Capital. The meaningful sponsors for the fund in investment in the same round are Vida Ventures, Two River, TPG. In the next rounds fund is usually obtained by Perceptive Advisors, Pontifax, Commercial Street Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| A8 New Media Group Ltd | China, Guangdong, Shenzhen |
| Bayer Trendlines Ag Innovation Fund | - |
| Boule Diagnostics | Skane Lan, Spånga, Sweden |
| Broadmedia Corporation | Japan, Tokyo |
| Bullet Time Venture Partners | Boulder, Colorado, United States |
| CURO Financial Technologies | Kansas, United States, Wichita |
| Dingchu Investment | China, Shanghai |
| Fibria Celulose S.A. | Brazil, São Paulo, Sao Paulo |
| Fondation d'Aide aux Entreprises | Geneva, Geneve, Switzerland |
| Global Frontier Partners | Bangalore, India, Karnataka |
| Guohua Capital | China, Guangdong, Shenzhen |
| Huangjin Gongsi | China, Futian, Guangdong |
| Impact USA | California, San Francisco, United States |
| Jinhua Duanxuan | - |
| Malta Enterprise | Central Region, Malta, Valletta |
| Open Innovation Ventures | Missouri, St Louis, United States |
| Pangloss International | - |
| Rakon GPS Technologies Limited | Auckland, Auckland, New Zealand |
| Shanghai Chenguoliang Yingxiao Cehua Shiwu Suo | China, Shanghai |
| Tech Coast Angels San Diego | California, San Diego, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ByHeart | $95M | 13 May 2024 | New York, New York, United States | ||
ByHeart | $90M | 26 Jul 2021 | New York, New York, United States | ||
| $77M | 05 Jan 2021 | San Diego, California, United States | |||
Dewpoint Therapeutics | $77M | 29 Sep 2020 | Cambridge, Massachusetts, United States | ||
ByHeart | $70M | 15 Apr 2020 | New York, United States | ||
Kronos Bio | $18M | 05 Jun 2018 | California, United States | ||
Allogene Therapeutics | $411M | 19 Apr 2018 | South San Francisco, California, United States |
– ByHeart is a NYC-based baby nutrition company.
– Company raised $90M in series B funding.
– The round was led by D1 Capital Partners with participation from OCV Partners, Polaris Partners, Bellco Capital, Two River and Red Sea Ventures – all of whom also invested in ByHeart’s Series A – as well as new investment from AF Ventures, and Gaingels.
– The new capital will be used to launch the company’s first formula, as well as to advance its innovation pipeline of mom and baby products.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ByHeart | $95M | 13 May 2024 | New York, New York, United States | ||
ByHeart | $90M | 26 Jul 2021 | New York, New York, United States | ||
| $77M | 05 Jan 2021 | San Diego, California, United States | |||
Dewpoint Therapeutics | $77M | 29 Sep 2020 | Cambridge, Massachusetts, United States | ||
ByHeart | $70M | 15 Apr 2020 | New York, United States | ||
Kronos Bio | $18M | 05 Jun 2018 | California, United States | ||
Allogene Therapeutics | $411M | 19 Apr 2018 | South San Francisco, California, United States |
